Drugs & Targets FDA grants IceCure clearance for expanded indications of cryoablation technology and regulatory approval of MultiSense system January 10, 2020Vol.46 No.02
Drugs & Targets Canada approves treatment for relapsed/refractory chronic lymphocytic leukemia as part of Project Orbis collaboration January 10, 2020Vol.46 No.02
Drugs & Targets FDA approves Lynparza as first-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer January 03, 2020Vol.46 No.01
Drugs & Targets FDA approves Xtandi for metastatic castration-sensitive prostate indication January 03, 2020Vol.46 No.01
Drugs & Targets FDA approves treatment for patients with HER2-positive breast cancer who have progressed on available therapies January 03, 2020Vol.46 No.01
Drugs & Targets FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer January 03, 2020Vol.46 No.01
Drugs & Targets FDA grants Avatrombopag Orphan Drug Designation for chemotherapy-induced thrombocytopenia January 03, 2020Vol.46 No.01
Drugs & Targets Karyopharm submits NDA for Xpovio for relapsed or refractory diffuse large B-cell lymphoma January 03, 2020Vol.46 No.01
Drugs & Targets Amgen and Allergan submit BLA for biosimilar candidate to Rituxan January 03, 2020Vol.46 No.01
Drugs & Targets China approves Zejula as maintenance therapy for recurrent ovarian cancer January 03, 2020Vol.46 No.01
